HIV protease inhibitors

Patent metadata

Field	Value
Publication number	US-11352329-B2
Application number	US-202016925096-A
Country	US
Kind code	B2
Filing date	Jul 9, 2020
Priority date	Oct 13, 2017
Publication date	Jun 7, 2022
Grant date	Jun 7, 2022

Abstract

The invention provides a compound of Formula I:or a pharmaceutically acceptable salt thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of Formula I, processes for preparing compounds of Formula I, therapeutic methods for treating the proliferation of the HIV virus, treating AIDS or delaying the onset of AIDS symptoms in a mammal using compounds of Formula I.

First claim

What is claimed is:

1. A compound of the formula

or a pharmaceutically acceptable salt thereof.

2. A compound of the formula

or a pharmaceutically acceptable salt thereof.

3. A compound of the formula

or a pharmaceutically acceptable salt thereof.

4. A compound of the formula

or a pharmaceutically acceptable salt thereof.

5. A compound of the formula

or a pharmaceutically acceptable salt thereof.

Assignees

• Gilead Sciences Inc

Inventors

• Cai Zhenhong R
• Cho Aesop
• Gonzalez Buenrostro Ana Zurisadai
• Han Xiaochun
• Jabri Salman Y
• Mcfadden Ryan
• Qi Yingmei
• Voigt Johannes
• Xu Jie
• Xu Lianhong
• Yang Hong

Classifications

• A61P31/18 Primary

  for HIV · CPC title

• C07D403/10

  linked by a carbon chain containing aromatic rings · CPC title

• C07D417/10

  linked by a carbon chain containing aromatic rings · CPC title

• C07D401/10 Primary

  linked by a carbon chain containing aromatic rings · CPC title

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title